RPT-Strong Merck cancer drug sales upstage rival Bristol-Myers
April 29, 2015 at 07:00 AM EDT
April 28 (Reuters) - Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.